{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:44:00Z","timestamp":1790030640268,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.radonc.2020.03.025","type":"journal-article","created":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T11:24:14Z","timestamp":1585394654000},"page":"65-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["DAHANCA 28: A phase I\/II feasibility study of hyperfractionated, accelerated radiotherapy with concomitant cisplatin and nimorazole (HART-CN) for patients with locally advanced, HPV\/p16-negative squamous cell carcinoma of the oropharynx, hypopharynx, larynx and oral cavity"],"prefix":"10.1016","volume":"148","author":[{"given":"Mette","family":"Saks\u00f8","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian R\u00f8nn","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper Grau","family":"Eriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Overgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2020.03.025_b0005","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2147\/CLEP.S103591","article-title":"The Danish Head and Neck Cancer database","volume":"8","author":"Overgaard","year":"2016","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.radonc.2020.03.025_b0010","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrc.2016.18","article-title":"Radiation oncology in the era of precision medicine","volume":"16","author":"Baumann","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.radonc.2020.03.025_b0015","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/S0959-8049(17)30416-1","article-title":"Improving radiotherapy of squamous cell carcinoma of the head and neck (HNSCC) through a continuous process of biological based clinical trials \u2212 a 40-year experience from the Danish Head and Neck Cancer Group \u2013 DAHANCA","volume":"72","author":"Overgaard","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2020.03.025_b0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0167-8140(97)00220-X","article-title":"A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5\u201385","volume":"46","author":"Overgaard","year":"1998","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.03.025_b0025","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(03)14361-9","article-title":"Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial","volume":"362","author":"Overgaard","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2020.03.025_b0030","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3109\/0284186X.2014.992547","article-title":"Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study","volume":"54","author":"Bentzen","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2020.03.025_b0035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0167-8140(92)90242-M","article-title":"Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy","volume":"25","author":"Horiot","year":"1992","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.03.025_b0040","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0360-3016(00)00663-5","article-title":"A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003","volume":"48","author":"Fu","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.03.025_b0045","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1080\/0284186X.2019.1658897","article-title":"A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma","volume":"58","author":"Saks\u00f8","year":"2019","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2020.03.025_b0050","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0140-6736(06)69121-6","article-title":"Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis","volume":"368","author":"Bourhis","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2020.03.025_b0055","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/1053-4296(92)90007-8","article-title":"The role of altered fractionation in head and neck cancers","volume":"2","author":"Peters","year":"1992","journal-title":"Sem Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.03.025_b0060","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1080\/0284186X.2019.1629012","article-title":"DAHANCA 9 \u2013 a randomized multicenter study to compare accelerated normo-fractionated radiotherapy with accelerated hyperfractionated radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC)","volume":"58","author":"Evensen","year":"2019","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2020.03.025_b0065","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1056\/NEJM199806183382503","article-title":"Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer","volume":"338","author":"Brizel","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2020.03.025_b0070","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1200\/JCO.2004.12.193","article-title":"Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy","volume":"22","author":"Huguenin","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.03.025_b0075","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.ijrobp.2008.05.042","article-title":"Impact of adding concomitant chemotherapy to hyperfractionated accelerated radiotherapy for advanced head-and-neck squamous cell carcinoma","volume":"73","author":"Nuyts","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.03.025_b0080","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s00066-013-0481-4","article-title":"Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer","volume":"190","author":"Budach","year":"2014","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2020.03.025_b0085","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00066-003-1106-0","article-title":"Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors: results of a phase I-II trial","volume":"179","author":"Kuhnt","year":"2003","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2020.03.025_b0090","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00066-019-01511-z","article-title":"Addition of chemotherapy to hyperfractionated radiotherapy in advanced head and neck cancer\u2014a meta-analysis","volume":"195","author":"Haussmann","year":"2019","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2020.03.025_b0095","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/S0959-8049(17)30415-X","article-title":"What is the most effective treatment for head and neck squamous cell carcinoma? An individual patient data network meta-analysis from the MACH-NC and MARCH collaborative groups","volume":"72","author":"Petit","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2020.03.025_b0100","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jclinepi.2010.10.016","article-title":"Mixed treatment comparison meta-analysis of altered fractionated radiotherapy and chemotherapy in head and neck cancer","volume":"64","author":"Blanchard","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.radonc.2020.03.025_b0105","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.radonc.2012.09.017","article-title":"Scoring and classification of oropharyngeal carcinoma based on HPV-related p16-expression","volume":"105","author":"Lassen","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.03.025_b0110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.radonc.2017.09.019","article-title":"Consequences of introducing geometric GTV to CTV margin expansion in DAHANCA contouring guidelines for head and neck radiotherapy","volume":"126","author":"Hansen","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.03.025_b0115","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.oraloncology.2018.10.034","article-title":"Target volume selection and delineation (T and N) for primary radiation treatment of oral cavity, oropharyngeal, hypopharyngeal and laryngeal squamous cell carcinoma","volume":"87","author":"Gr\u00e9goire","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.radonc.2020.03.025_b0120","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3109\/0284186X.2013.864050","article-title":"Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC)","volume":"53","author":"Metwally","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2020.03.025_b0125","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3109\/0284186X.2015.1028591","article-title":"A longitudinal study of follow-up activities after curative treatment for head and neck cancer","volume":"54","author":"Pagh","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2020.03.025_b0130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.radonc.2012.01.002","article-title":"Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer","volume":"103","author":"Mortensen","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.03.025_b0135","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1080\/0284186X.2017.1346384","article-title":"Analysis of CT-verified loco-regional recurrences after definitive IMRT for HNSCC using site of origin estimation methods","volume":"56","author":"Zukauskaite","year":"2017","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2020.03.025_b0140","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0167-8140(19)30207-5","article-title":"OC-041 DAHANCA 28a: phase I\/II study of acc. hyperfractionated RT, cisplatin and nimorazole in P16-LAHNSCC","volume":"132","author":"Saks\u00f8","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.03.025_b0145","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.oraloncology.2017.11.025","article-title":"Altered fractionation radiotherapy combined with concurrent low-dose or high-dose cisplatin in head and neck cancer: a systematic review of literature and meta-analysis","volume":"76","author":"Szturz","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.radonc.2020.03.025_b0150","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1002\/cncr.25189","article-title":"Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer","volume":"116","author":"Newlin","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2020.03.025_b0155","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ijrobp.2009.12.046","article-title":"Phase II trial of hyperfractionated intensity-modulated radiation therapy and concurrent weekly cisplatin for stage III and IVa head-and-neck cancer","volume":"79","author":"Maguire","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.03.025_b0160","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0167-8140(17)30291-8","article-title":"SP-010: update of the meta-analysis of chemotherapy in head and neck cancer (MACH-NC)","volume":"122","author":"Blanchard","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.03.025_b0165","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.radonc.2016.03.005","article-title":"Phase I trial of 18F-fludeoxyglucose based radiation dose painting with concomitant cisplatin in head and neck cancer","volume":"120","author":"Rasmussen","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.03.025_b0170","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.radonc.2017.04.004","article-title":"Prognostic value of dynamic hypoxia PET in head and neck cancer: results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial","volume":"124","author":"Welz","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.03.025_b0175","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1080\/0284186X.2017.1364867","article-title":"Late mucosal ulcers in dose-escalated adaptive dose-painting treatments for head-and-neck cancer","volume":"57","author":"Olteanu","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2020.03.025_b0180","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3109\/0284186X.2014.998279","article-title":"Socioeconomic position and stage at diagnosis of head and neck cancer \u2013 a nationwide study from DAHANCA","volume":"54","author":"Olsen","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2020.03.025_b0185","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.radonc.2007.06.004","article-title":"Late swallowing dysfunction and dysphagia after radiotherapy for pharynx cancer: frequency, intensity and correlation with dose and volume parameters","volume":"85","author":"Jensen","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.03.025_b0190","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.ijrobp.2009.09.036","article-title":"Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck cancer","volume":"78","author":"Chen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.03.025_b0195","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1080\/0284186X.2019.1643037","article-title":"Osteoradionecrosis of the mandible after radiotherapy for head and neck cancer: risk factors and dose-volume correlations","volume":"58","author":"Aarup-Kristensen","year":"2019","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2020.03.025_b0200","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.radonc.2016.08.009","article-title":"Reduction of the dose of radiotherapy to the elective neck in head and neck squamous cell carcinoma; a randomized clinical trial. Effect on late toxicity and tumor control","volume":"122","author":"Nevens","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.03.025_b0205","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.ijrobp.2017.12.223","article-title":"Factors impacting the development of neck fibrosis in head and neck cancer patients following radiation therapy","volume":"100","author":"Pratson","year":"2018","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.03.025_b0210","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijrobp.2019.02.025","article-title":"Optimized hypofractionation can markedly improve tumor control and decrease late effects for head and neck cancer","volume":"104","author":"Shuryak","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.03.025_b0215","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.radonc.2012.09.015","article-title":"FAZA PET\/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial","volume":"105","author":"Mortensen","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.03.025_b0220","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/0284186X.2019.1695065","article-title":"DAHANCA 33: functional image guided dose-escalated radiotherapy to patients with hypoxic squamous cell carcinoma of the head and neck (NCT02976051)","volume":"59","author":"Saks\u00f8","year":"2020","journal-title":"Acta Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814020301560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814020301560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:10:07Z","timestamp":1759122607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814020301560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":44,"alternative-id":["S0167814020301560"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2020.03.025","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DAHANCA 28: A phase I\/II feasibility study of hyperfractionated, accelerated radiotherapy with concomitant cisplatin and nimorazole (HART-CN) for patients with locally advanced, HPV\/p16-negative squamous cell carcinoma of the oropharynx, hypopharynx, larynx and oral cavity","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2020.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}